Prenetics Global Limited (NASDAQ:PRE) Short Interest Update

Prenetics Global Limited (NASDAQ:PRE) was the target of a significant growth in short interest during the month of December. As of December 15th, there was short interest totalling 41,900 shares, a growth of 23.6% from the November 30th total of 33,900 shares. Based on an average daily trading volume, of 14,000 shares, the days-to-cover ratio is presently 3.0 days. Currently, 0.5% of the company’s stock are short sold.

Prenetics Global Stock Down 0.5 %

Shares of NASDAQ PRE traded down $0.03 during midday trading on Tuesday, hitting $5.80. The stock had a trading volume of 10,471 shares, compared to its average volume of 47,859. The business’s 50 day moving average is $4.90 and its 200-day moving average is $5.11. Prenetics Global has a 52 week low of $2.85 and a 52 week high of $7.84. The company has a market cap of $52.99 million, a P/E ratio of -1.45 and a beta of -0.18.

Prenetics Global (NASDAQ:PRE) last announced its quarterly earnings data on Monday, October 7th. The company reported ($0.88) earnings per share for the quarter. Prenetics Global had a negative return on equity of 16.45% and a negative net margin of 191.73%. The firm had revenue of $5.94 million during the quarter. As a group, analysts expect that Prenetics Global will post -3.3 EPS for the current fiscal year.

Analysts Set New Price Targets

Separately, Cantor Fitzgerald reiterated an “overweight” rating and issued a $9.00 price target on shares of Prenetics Global in a research note on Wednesday, December 4th.

Prenetics Global Company Profile

Prenetics Global Limited, a genomics-driven health sciences company, engages in revolutionizing prevention, early detection, and treatment. It offers CircleDNA, a prevention arm that uses whole exome sequencing to offer comprehensive consumer DNA test. The company also, through its joint venture, Insighta, engages in pioneering multi-cancer early detection technologies.